SCHEMBL19254673

SCHEMBL19254673

CCc1nn(-c2nc(Cl)ncc2C(F)(F)F)c2ccc(C#N)cc12

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM2 Q14416 1/20 0.36
LRRK2 Q5S007 4/20 0.34
GUCY1A1 Q02108 1/20 0.33
GUCY1B1 Q02153 1/20 0.33
KCNH2 Q12809 1/20 0.33
CCNT1 O60563 2/20 0.32
CCNE1 P24864 2/20 0.32
CDK2 P24941 2/20 0.32
CDK9 P50750 2/20 0.32
CCNK O75909 1/20 0.32
CDK12 Q9NYV4 1/20 0.32
JUN P05412 1/20 0.31
NFKB1 P19838 1/20 0.31
NFKB2 Q00653 1/20 0.31
RELA Q04206 1/20 0.31
CNR1 P21554 1/20 0.31
PSEN1 P49768 1/20 0.31
PSEN2 P49810 1/20 0.31
APH1B Q8WW43 1/20 0.31
NCSTN Q92542 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17682937 0.87 GRM2 (0.36) GRM2LRRK2CCNKCDK12PSEN1
SCHEMBL19532543 0.85 SCARB1 (0.35) GUCY1A1GUCY1B1KCNH2CDK9CDK7
SCHEMBL19540762 0.84 RARG (0.37) GRM2LRRK2PSEN1PSEN2APH1B
SCHEMBL17683379 0.78 KCNH2 (0.35) GUCY1A1GUCY1B1KCNH2CDK9CDK4
SCHEMBL23729044 0.74 LRRK2 (0.42) LRRK2PTK2
SCHEMBL30007251 0.73 CDC7 (0.46) GRM2CDK2PSEN1PSEN2APH1B
SCHEMBL28817261 0.73 CDC7 (0.46) GRM2CDK2PSEN1PSEN2APH1B
SCHEMBL17683276 0.73 LRRK2 (0.41) LRRK2PTK2
SCHEMBL17683275 0.71 EGFR (0.41) LRRK2KCNH2
SCHEMBL30750938 0.71 CDC7 (0.46) GRM2CDK2TRPV4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3205650-B1 EGFR INHIBITOR, AND PREPARATION AND APPLICATION THEREOF SHANGHAI HANSOH BIOMEDICAL CO LTD (CN) 2021-08-04 EP disclosed
US-10259820-B2 EGFR inhibitor, preparation method and use thereof SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) 2019-04-16 US disclosed
US-20170313714-A1 EGFR INHIBITOR, PREPARATION METHOD AND USE THEREOF SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) 2017-11-02 US disclosed
EP-3205650-A1 EGFR INHIBITOR, AND PREPARATION AND APPLICATION THEREOF Shanghai Hansoh Biomedical Co., Ltd. (CN) 2017-08-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170313714-A1 EGFR INHIBITOR, PREPARATION METHOD AND USE THEREOF EGFR, ERBB2, ERBB4 GRM2 2740/4885LRRK2 266/4885GUCY1A1 2201/4885
US-10259820-B2 EGFR inhibitor, preparation method and use thereof EGFR, ERBB2, ERBB4 GRM2 2740/4885LRRK2 266/4885GUCY1A1 2201/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.